Eli Lilly and Novartis back Cylene's latest $12m funding in a round reportedly extended more than three years.
US-based Cylene Pharmaceuticals has raised $12m from its existing venture capital and corporate venturing investors in its series C round reportedly extended over more than three years.
Drugs companies Eli Lilly and Novartis through their corporate venturing divisions reinvested in the C round alongside venture capital firms Sanderling Ventures, HBM BioVentures, BioVentures Investors, Mitsui and Morningside Venture Investments.
News provider VentureWire said the latest $12m was an extension to Cylene’s $44m C round that closed in January 2007.
The C…
